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is emerging as an attractive alternative to currently used anti-
infectious protocols in at-risk patients, such as those under-
going hematopoietic stem cells transplantation [1]. As more
extensively tested in oncologic patients, two main strategies
may be used: ﬁrstly, the infusion of autologous or donor-
derived total or pathogen-speciﬁc T cells, and secondly, the
use of pathogen-speciﬁc engineered T cells. In the latest
approach, it is included the redirection of T cells by using the
so-called chimeric antigen receptors (CARs).
CARs were ﬁrstly described in the late 1980s [2], and after
design and technical improvements have recently reached the
clinics with several ongoing clinical trials. In 2013, they were
considered by Science magazine as important turning points in
cancer immunotherapy—the major scientiﬁc breakthrough of
that year [3]. In brief, CARs are artiﬁcial receptors constituted
by a speciﬁc antigen-binding domain (usually, but not neces-
sarily, represented by a single chain antibody fragment—scFv),
an extracellular hinge region, a transmembrane domain, and a T
cell receptor–derived intracellular signaling domain capable of
triggering T cell activation [4]. This construct is used to
transduce T cells which can therefore acquire a deﬁnite antigen
speciﬁcity. Put simply, CARs may be considered as featuring the
binding speciﬁcity of a monoclonal antibody (mAb) associated
with the effector functions of a T cell.
The main potential advantages of CARs are related to their
capacity of recognizing antigens in a major histocompatibility
complex (MHC)-independent manner, making them attractive
immunotherapeutic tools. Ideally, the same CAR construct may
be used effectively in different MHC-unrelated patients, one of
the main limitations in the actual use of T cell–based therapy.
Another important potential advantage is the capability of
bypassing escape mechanisms based on MHC down-regulation,
which may be put in practice by both neoplastic cells and in-
fectious agents [5,6]. On the other hand, the lack of MHC
control in T cell activation is the main theoretical riskClinical Microbiology and Infection © 2015 European Society of Cassociated with aspeciﬁc CAR-triggered T cell activation with
subsequent off-target toxicity.
As clinical microbiologists, in our opinion, we must ask
whether there is a place for CARs as prophylactic or thera-
peutic anti-infectious agents. This topic has been only partially
addressed, with very few anti-infectious CARs described in
the literature [7]. However there are several aspects which
could make them an effective tool in this setting. First of all,
their in vivo half-life is sufﬁcient to guarantee an immunologic
patrolling against speciﬁc pathogens during temporary periods
of immunosuppression, such as during the peritransplantation
period in hematopoietic stem cell transplantation patients.
Importantly, several constructs have already been described
as capable of conferring resistance to several immunosup-
pressive agents to the transduced T cells [8]. Moreover, the
overall activity of infused T cells could be theoretically
modulated by the infusion of selected T cells, thus allowing a
preferential cytotoxic activity vs. a preferential cytokine
pattern modulation. This could be particularly important for
opportunistic infection (e.g. invasive fungal infection) where
the speciﬁc cytokine patterns may profoundly modulate the
pathogen’s aggressiveness [9]. Finally, their use could be hy-
pothesized in chronic viral infections, with latency sites
cleared neither by available therapies nor by the host’s im-
mune system [10].
This last point allows to introduce the main drawback of the
CAR approach: the need to target surface-exposed accessible
antigens, which should also reach sufﬁcient levels to trigger the
CAR’s activation. In our opinion, this aspect has not been suf-
ﬁciently addressed by the groups working on CARs, especially
the few working with their possible anti-infectious applications.
In other words, one must select the best mAb to be used as
CAR’s binding domain. Indeed, most of the groups that have
published on CARs have a strong background on cellular
immunology but are not speciﬁc experts in the mAb ﬁeld. The
choice of the best mAb is particularly important in the infec-
tious ﬁeld, thus allowing high speciﬁcity of action, limiting the
inherent risk of off-target toxicity. Moreover, the ideal mAb
should be endowed with such cross-reactivity within a given
group of pathogens of interest to allow the coverage of as many
potential pathogens as possible, but without aspeciﬁc activation
by less pathogenic species.Clin Microbiol Infect 2015; 21: 715–716
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